# OAKHAM
## Cancer Incidence by Sex, 1993 - 1997
### Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | Obs | SIR | | Exp | Obs | SIR |
|---|---|---|---|---|---|---|---|
| **Bladder, Urinary** | | | | **Melanoma of Skin** | | | |
| Male | 0.87 | 0 | NC* | Male | 0.56 | 1 | NC* |
| Female | 0.27 | 0 | NC* | Female | 0.41 | 0 | NC* |
| Total | 1.14 | 0 | NC* | Total | 0.97 | 1 | NC* |
| **Brain and Other Central Nervous System** | | | | **Multiple Myeloma** | | | |
| Male | 0.32 | 0 | NC* | Male | 0.17 | 0 | NC* |
| Female | 0.25 | 0 | NC* | Female | 0.13 | 0 | NC* |
| Total | 0.57 | 0 | NC* | Total | 0.30 | 0 | NC* |
| **Breast** | | | | **Non-Hodgkin's Lymphoma** | | | |
| Male | 0.06 | 1 | NC* | Male | 0.73 | 2 | NC* |
| Female | 5.02 | 4 | NC* | Female | 0.54 | 0 | NC* |
| Total | 5.08 | 5 | 98 | Total | 1.28 | 2 | NC* |
| **Cervix Uteri** | | | | **Oral Cavity and Pharynx** | | | |
| | | | | Male | 0.62 | 0 | NC* |
| Female | 0.36 | 0 | NC* | Female | 0.25 | 1 | NC* |
| | | | | Total | 0.87 | 1 | NC* |
| **Colon / Rectum** | | | | **Ovary** | | | |
| Male | 2.19 | 1 | NC* | | | | |
| Female | 1.72 | 1 | NC* | Female | 0.62 | 1 | NC* |
| Total | 3.91 | 2 | NC* | | | | |
| **Esophagus** | | | | **Pancreas** | | | |
| Male | 0.33 | 1 | NC* | Male | 0.34 | 0 | NC* |
| Female | 0.09 | 0 | NC* | Female | 0.29 | 0 | NC* |
| Total | 0.41 | 1 | NC* | Total | 0.62 | 0 | NC* |
| **Hodgkin's Disease** | | | | **Prostate** | | | |
| Male | 0.16 | 0 | NC* | Male | 5.21 | 5 | 96 |
| Female | 0.12 | 0 | NC* | | | | |
| Total | 0.29 | 0 | NC* | | | | |
| **Kidney and Renal Pelvis** | | | | **Stomach** | | | |
| Male | 0.54 | 0 | NC* | Male | 0.38 | 0 | NC* |
| Female | 0.28 | 0 | NC* | Female | 0.19 | 0 | NC* |
| Total | 0.82 | 0 | NC* | Total | 0.57 | 0 | NC* |
| **Larynx** | | | | **Testis** | | | |
| Male | 0.32 | 1 | NC* | Male | 0.23 | 0 | NC* |

| | Exp | Obs | SIR | | | Exp | Obs | SIR |
|---|---|---|---|---|---|---|---|---|
| Female | 0.08 | 0 | NC* | | | | | |
| Total | 0.40 | 1 | NC* | | | | | |
| **Leukemia** | | | | | **Thyroid** | | | |
| Male | 0.41 | 0 | NC* | | Male | 0.12 | 0 | NC* |
| Female | 0.28 | 0 | NC* | | Female | 0.30 | 0 | NC* |
| Total | 0.69 | 0 | NC* | | Total | 0.42 | 0 | NC* |
| **Liver and Intrahepatic Bile Ducts** | | | | | **Uteri, Corpus and Uterus, NOS** | | | |
| Male | 0.18 | 1 | NC* | | | | | |
| Female | 0.06 | 0 | NC* | | Female | 0.95 | 1 | NC* |
| Total | 0.24 | 1 | NC* | | | | | |
| **Lung and Bronchus** | | | | | **All Sites / Types** | | | |
| Male | 2.82 | 5 | 177 | | Male | 17.82 | 18 | 101 |
| Female | 1.89 | 1 | NC* | | Female | 15.18 | 9 | 59 |
| Total | 4.71 | 6 | 127 | | Total | 33.00 | 27 | 82 |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the **p** ≤ 0.05 level

~ indicates statistical significance at the **p** ≤ 0.01 level, as well as at the **p** ≤ 0.05 level

^ indicates statistical significance at the **p** ≤ 0.001 level, as well as at the **p** ≤ 0.05 and **p** ≤ 0.01 levels